ReviewOncology letters2025
Progress of MRI-based radiomics and deep learning for predicting the prognosis of locally advanced rectal cancer (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Automated deep learning model for predicting pathological complete response in rectal cancer: A tool to organ-preserving strategies.International journal of colorectal disease · 2026Article
- A new paradigm in postoperative colorectal cancer surveillance: integrating advanced imaging and multi-omics.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rectal cancer (RC) ranks among the most common malignant tumors worldwide, with ~30% of patients presenting at a locally advanced stage at the time of diagnosis. The standard treatment for locally advanced RC (LARC) combines neoadjuvant chemoradiotherapy (nCRT) with total mesorectal excision. While this treatment paradigm has been effective in reducing the local recurrence rate, its efficacy in enhancing overall survival and disease-free survival is still limited. Consequently, the identification of adverse prognostic factors in patients with LARC is crucial for improving long-term survival outcomes. Traditional imaging methods offer limited predictive power for early diagnosis, treatment efficacy assessment and prognosis in LARC. Recent advancements in MRI-based radiomics and deep learning (DL), leveraging high-dimensional feature extraction and nonlinear modeling, have markedly enhanced prognostic predictive performance. Single-sequence MRI radiomics models derived from pre-nCRT imaging demonstrate areas under the curve (AUC) of 0.79-0.87 for predicting local recurrence and distant metastasis. Multiparametric radiomic models further improve predictive accuracy, achieving AUCs of 0.81-0.83. Delta radiomics, which captures temporal-spatial heterogeneity evolution in tumors during therapy, elevates AUC performance to 0.77-0.89. Notably, DL-based models exhibit superior and more stable predictive capabilities, with concordance indices (C-indices) ranging from 0.82 to 0.94. This paper reviews recent progress in MRI-based radiomics and DL for predicting the prognosis of patients with LARC subjected to nCRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.